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Purpose:  Orbital  fibroblasts  are  now  recognized  as  the  key  effectors  in  the  development  of  thyroid  associated
ophthalmopathy (TAO). TAO is clinically apparent in approximately 50% of patients with Graves’ hyperthyroidism. High
levels of plasma free fatty acids (FFAs) are frequently seen in patients with hyperthyroidism. Palmitate is one of the most
abundant FFAs in plasma and aggravates inflammation by promoting secretion of pro-inflammatory cytokines in various
cells. In the present study, we characterized orbital fibroblasts from patients with TAO and then examined the effect of
palmitate on the production of pro-inflammatory cytokines and hyaluronic acid (HA) in orbital fibroblasts.
Methods: Orbital fat explants were obtained from patients with TAO undergoing orbital decompression surgery (n=5).
The fibroblasts were characterized by antibodies specific for fibroblast markers and Thy-1 (cluster differentiation 90,
CD90) by immunostaining and flow cytometry. We then investigated the capability of orbital fibroblasts to secrete
cytokines and HA in response to interleukin (IL)-1β using an enzyme-linked immunosorbent assay (ELISA). The effect
of palmitate on cytokine and HA production in orbital fibroblasts was examined at the protein level by ELISA and at the
mRNA level by quantitative real time RT–PCR. The level of phosphorylation of mitogen-activated protein kinase
(MAPK)s, including p38 MAPK (p38), extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK),
was measured by immunoblot analysis. We then examined the role of MAPKs on palmitate-induced cytokine production
using specific inhibitors to p38, ERK, and JNK, respectively.
Results: The orbital fibroblasts from patients with TAO were Thy-1- positive fibroblasts (>90%) with the ability to secrete
IL-6, IL-8, monocyte chemotactic protein-1 (MCP-1), and HA in response to IL-1β. Treatment with palmitate induced
significant production of IL-6 and MCP-1, but not IL-8 and HA, in orbital fibroblasts. IL-6 and MCP-1 expression by
palmitate were differentially regulated by MAPKs. IL-6 expression was mediated by the p38, ERK, JNK pathways,
whereas MCP-1 expression was mediated by ERK and JNK, but not by p38, in palmitate-treated orbital fibroblasts.
Conclusions: We show the possible involvement of palmitate in the promotion of inflammation within orbital tissues.
This finding may be helpful for understanding the development of TAO in patients with hyperthyroidism.
Thyroid  associated  ophthalmopathy  (TAO)  is  an
autoimmune disease affecting orbital and periorbital tissues.
The main clinical features of TAO, including upper eyelid
retraction, edema, and erythema of the periorbital tissues and
conjunctivae, as well as exophthalmos, are mainly due to
swelling of the fatty and muscular orbital tissues [1]. The
edematous  changes  that  occur  in  TAO  orbital  tissues  are
caused by infiltration of inflammatory cells, accumulation of
extracellular  matrix  (ECM)  proteins,  proliferation  of
fibroblasts, and an increased amount of fatty tissue [2].
Orbital  fibroblasts  are  now  recognized  as  the  key
effectors in the development of TAO and contribute to the
development of TAO in several aspects. Orbital fibroblasts
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are not only main target cells for auto-antibodies present in
patients with Graves’ ophthalmopathy but are also involved
in inflammation by producing inflammatory cytokines and
hyaluronic  acid  (HA).  Thus,  many  scientists  have  been
interested in factors triggering orbital fibroblasts to secrete
pro-inflammatory cytokines. In addition to autoantibodies,
ganglioside [3], and cluster differentiation 154 (CD154), the
CD40  cognate  ligand  [4],  induces  secretion  of  pro-
inflammatory cytokines from orbital fibroblasts.
TAO is associated with hyperthyroidism, although it may
occur in hypothyroid or euthyroid patients. TAO is clinically
apparent  in  approximately  50%  of  patients  with  Graves’
hyperthyroidism [5]. Glucose intolerance and high levels of
plasma free fatty acids (FFAs) are frequently seen in patients
with  hyperthyroidism,  and  these  may  be  caused  by  the
hypermetabolic state due to elevated serum thyroid hormones
[6].  Elevated  plasma  FFAs  are  associated  with  insulin
resistance in skeletal muscle [7] and endothelial dysfunction
in the cardiovascular system [8]. Of various serum FFAs,
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1467palmitate (C16:0) has received the most attention for its ability
to induce cardiomyocyte cell death [9]. In addition to cardiac
toxicity,  palmitate  not  only  inhibits  insulin  signaling  in
skeletal muscle cells [10] and induces cell death in pancreatic
β-cells [11], it also aggravates inflammation by promoting
secretion  of  pro-inflammatory  cytokines  in  various  cells
[12-16]. Thus, we thought that palmitate may also induce the
secretion  of  pro-inflammatory  cytokines  from  orbital
fibroblasts, although there is not yet scientific evidence that
supports the correlation between plasma FFA levels and the
development of TAO.
In this study, we examined the possible involvement of
FFAs,  particularly  palmitate,  in  the  promotion  of
inflammation  within  orbital  tissues  and  in  the  subsequent
development  of  TAO.  We  initially  characterized  orbital
fibroblasts from patients with TAO. We assessed the effect of
palmitate on the production of pro-inflammatory cytokines
and HA in orbital fibroblasts.
METHODS
Reagents  and  antibodies:  Palmitate,  fumonisin  B1,  and
triacsin C were obtained from Sigma-Aldrich Co. Ltd (St.
Louis, MO). The inhibitors, SB 203580 (p38 MAPK [p38]),
PD 98059 (MAPK kinase 1 [MEK1]), and SP 600125 (c-Jun
N-terminal  kinase  [JNK]/  stress  activated  protein  kinase
[SAPK]) were purchased from Calbiochem (La Jolla, CA).
Fumonisin B1, triacsin C, SB 203580, PD 98059, and SP
600125  were  dissolved  in  dimethyl  sulfoxide  or  methyl
alcohol or H2O. The final vehicle concentration was adjusted
to 0.1% (v/v), and the control medium contained the same
quantity of vehicle. Antibodies against phospho-p38, p38,
phospho-ERK, ERK, phospho-JNK, JNK, and PDI (disulfide
isomerase) were obtained from Cell Signaling Technology
(Beverly,  MA).  Antibodies  against  vimentin,  α-smooth
muscle actin, and cytokeratin were purchased from Abcam
(Cambridge, UK). Antibody against factor VIII was obtained
from Sigma-Aldrich. PE-Cy5-conjugated anti-CD90 (Thy-1)
antibody and PE-Cy5-conjugated immunoglobulin G kappa
(IgGĸ) isotype were obtained from BD PharMingen (San Jose,
CA). anti-Glyceraldehyde-3-phosphate-dehydogenase (anti-
GAPDH)  antibody,  horseradish  peroxidase,  and  Cy3-
conjugated secondary antibodies were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA).
Establishment of orbital fat-derived fibroblasts: Orbital fat
explants were obtained as surgical waste during orbital bone
and fat decompression surgery in patients with TAO (n=5).
Before the decompression surgery, all patients with TAO had
experienced at least 6 months of inactive disease status with
a euthyroid condition. Patient characteristics are presented in
Table 1. Orbital fat explants were chopped in small pieces,
attached  to  plastic  culture  dishes,  and  covered  with
Dulbecco’s Modified Eagle’s medium (GIBCO BRL, Grand
Island,  NY)  supplemented  with  20  mM  HEPES  (Fisher
Scientific,  Atlanta,  GA),  10%  fetal  bovine  serum  (FBS;
GIBCO  BRL),  100  U/ml  of  penicillin,  and  100  μg/ml  of
streptomycin (Bio Whittaker Inc., Walkersville, MD). Dermal
fibroblasts were obtained from skin specimens of healthy
patients  without  TAO  undergoing  abdomen  reduction
surgery. Cultures were maintained at 37 °C in a 5% CO2
humidified  incubator  until  fibroblasts  reached  70%
confluence.  Non-adherent  cells  and  fat  tissues  were  then
removed, and the established fibroblasts were passaged with
gentle trypsin/EDTA treatment. Fibroblasts were not used for
studies  beyond  passage  7  from  the  initial  culture.  These
activities  were  undertaken  after  informed  consent  was
obtained from the donors, according to procedures approved
by  the  Institutional  Review  Board  of  Seoul  St.  Mary’s
Hospital (KC10TISE0743) and the tenets of the Declaration
of Helsinki.
Characterization  of  orbital  fat-derived  fibroblasts:
Fibroblasts were characterized by immunostaining and flow
cytometry. The expression patterns of fibroblast and non-
fibroblast markers were examined by immunostaining with
antibodies  against  vimentin,  α-smooth  muscle  actin,  PDI,
factor  VIII,  and  cytokeratin.  Cells  were  fixed  in  2%
paraformaldehyde in PBS and permeabilized by 5% Triton
X-100 in PBS. Fixed cells were rinsed with PBS and incubated
in blocking solution (0.1 M NH4Cl, 0.2% gelatin, 0.3% Triton
X-100 in PBS) for 20 min. The cells were then incubated
overnight  with  a  primary  antibody  against  the  designated
protein in an incubation solution (0.2% gelatin, 0.3% Triton
X-100, and 3% goat serum in PBS) at 4 °C. After washing
with PBS, cells were incubated with the corresponding Cy3-
conjugated secondary IgG at room temperature for 2 h. Nuclei
were  counterstained  for  15  min  with  4'-6-diamidino-2-
phenylindole (Sigma). The negative control was processed
without  primary  antibody.  Immunofluorescence  was
visualized by inverted fluorescence microscopy (IX71/IX51;
Olympus Corp., Tokyo, Japan). The Thy-1 CD90 expression
pattern was examined by flow cytometry with an antibody
against Thy-1. Cells were suspended in FACS buffer (0.05%
NaN3, 5% FBS, 95% PBS) and then incubated with PE-Cy5-
conjugated anti-Thy-1 antibody. PE-Cy5-conjugated IgG1 κ
isotype was used as a negative control. The cells were washed
twice with FACS buffer, resuspended, and analyzed by flow
cytometry (FACSCalibur, BD Bioscience).
Palmitate preparation: Palmitate was prepared, as described
previously [17]. In brief, to reduce endotoxin contamination,
palmitate was dissolved to a final concentration of 40 mM in
a solvent of 0.1 N NaOH/70% ethanol and added directly to
the cell culture media, where it could complex with BSA
already present in the culture media. Palmitate was used at
final concentrations of 100–400 μ.
Endotoxin assay: The level of endotoxin was measured using
a  chromogenic  endotoxin  assay  kit  (the  ToxinSensorTM
Endotoxin  Detection  System;  GenScript,  Piscataway,  NJ).
Briefly, reconstituted limulus amebocytes lysates was mixed
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1469with sample solution and the mixture was incubated at 37 °C
for 45 min. After incubation, chromogenic substrate solution
was added to the mixture and incubated at 37 °C for 6 min.
Color stabilizer was then added and the absorbance of each
reaction was read at 545 nm.
Cytokine assays: Fibroblasts were cultured to confluence and
treated for 1 h with or without a designated inhibitor, followed
by treatment with palmitate (100–400 μM) for 24 h. Culture
medium  was  analyzed  for  interleukin  (IL)-6,  IL-8,  and
monocyte chemotactic protein-1 (MCP-1) content using a
standard  sandwich  enzyme  linked  immunosorbent  assay
(ELISA)  kit  (R&D  Systems,  Minneapolis,  MN).  HA
concentration  was  determined  with  an  HA-ELISA  kit
(Echelon Biosciences, Salt Lake City, UT) according to the
manufacturer’s instructions.
Immunoblot analysis: Treated cells were removed from the
incubator at the designated time, placed on ice, and washed
three times with ice-cold PBS. The cells were then lysed for
30 min with RIPA lysis buffer (50 mM Tris-HCl [pH 7.4], 1%
Triton  X-100,  150  mM  NaCl,  0.1%  SDS,  0.5%  sodium
deoxycholate, 100 mM phenylmethylsulfonyl fluoride, 1 μg/
ml of leupeptin, 1 mM Na3VO4, and 1× Complete TM Protease
Inhibitor  Cocktail;  Santa  Cruz  Biotechnology).  Equal
amounts of protein were loaded onto 10%–15% SDS–PAGE
gels, electrophoresed, and transferred onto PVDF membranes
(Millipore, Bedford, MA). The membranes were blocked in
Tris-buffered  saline  with  0.05%  Tween-20  (TBST)
supplemented with 5% powdered milk or 5% BSA and then
incubated  with  a  primary  antibody  against  the  designated
protein. The blot was then washed with TBST and incubated
with a horseradish peroxidase-conjugated secondary antibody
in TBST plus 5% powdered milk. The bound antibodies were
detected  with  Super  Signal  Ultra  Chemiluminescence
Reagents (Pierce Biotechnology, Inc., Rockford, IL).
Quantitative Real Time-RT–PCR: IL-6 and MCP-1 mRNA
expression  was  determined  by  quantitative  real  time-RT–
PCR. Briefly, total RNA was extracted using a High Pure
RNA Isolation kit (Roche Diagnostics, Mannheim, Germany)
and converted to cDNA using an Advantage RT-for-PCR kit
(Clontech, Hampshire, UK), according to the manufacturer’s
instructions.  To  quantify  IL-6  and  MCP-1  mRNA,
quantitative real time RT–PCR was performed with a iQTM
SYBR® Supermix kit (Bio-Rad Laboratories, Hercules, CA)
in a Peltier Thermal Cycler-200 system (MJ Research, Berlin,
Germany). Real time PCR was performed in triplicate at 95 °C
for 3 min followed by 35 cycles of amplification (94 °C for
30 s, 68.3 °C for 30 s, and 72 °C for 30 s). The relative amounts
of IL-6 and MCP-1 mRNA were determined by subtracting
the  cycle  threshold  (Ct)  values  from  the  Ct  values  for
cyclophilin.  The  following  primers  for  IL-6,  MCP-1,  and
cyclophilin were used: For IL-6, forward primer (5′-AAA
TGC CAG CCT GCT GAC GAA C-3′) and reverse primer
(5′-AAC AAC AAT CTG AGG TGC CCA TGC TAC-3′).
For MCP-1, forward primer (5′-ATG CAA TCA ATG CCC
CAG TC-3′) and reverse primer (5′-TGC AGA TTC TTG
GGT TGT GG-3′). For cyclophilin, forward primer (5′-GCA
TAC GGG TCC TGG CAT CTT GTC C-3′) and reverse
primer (5′-ATG GTG ATC TTC TTG CTG GTC TTG-3′).
Statistical analyses: All results are expressed as mean±SD.
An  unpaired  Student’s  t-test  was  used  to  determine
differences from control values. Statistical software (SPSS
15.0; SPSS inc., Chicago, IL) was used for analysis, and
p<0.05 was considered statistically significant.
RESULTS
Characterization  of  orbital  fibroblasts  from  patients  with
TAO: Orbital fibroblasts, derived from orbital fat explants of
patients with TAO, were flat and elongated with processes
extending out from the ends of the cell bodies. We initially
examined  the  expression  of  fibroblast  markers  in  orbital
fibroblasts  by  immunostaining  to  characterize  the  orbital
fibroblast  phenotypes.  As  shown  in  Figure  1,  the  orbital
fibroblasts  stained  positively  for  vimentin  (a  fibroblast
marker), α-smooth muscle actin (a myofibroblast marker), and
protein  disulfide-isomerase  (a  fibroblast  marker)  but
negatively for factor VIII (an endothelial cell marker) and
cytokeratin (a keratinocyte marker).
Orbital  fibroblasts  are  heterogeneous  with  respect  to
surface  Thy-1  expression.  Thy-1-positive  and  negative
subpopulations play distinct roles in the development of TAO.
Therefore, we analyzed the proportion of Thy-1-positive and
negative cells by flow cytometry. Expression of Thy-1 in
fibroblasts derived from orbital fat explants of patients with
TAO in our system was relatively homogeneous and >90%
(Figure 2).
We next investigated the capability of orbital fibroblasts
to secrete cytokines and HA. Orbital fibroblasts were treated
with 10 ng/ml IL-1β for 24 h. Treatment with IL-1β induced
secretion of IL-6, IL-8, MCP-1, and HA by orbital fibroblasts.
The level of secretion of IL-6, IL-8, MCP-1 and HA increased
13.0  fold,  22.7  fold,  2.0  fold,  and  1.8  fold,  respectively,
compared with control levels (Figure 3). These results show
that orbital fibroblasts are Thy-1-positive fibroblasts with the
ability to secrete IL-6, IL-8, MCP-1, and HA in response to
IL-1β.
Effect of palmitate on IL-6 and MCP-1 secretion in orbital
fibroblasts:  Following  this,  we  examined  the  effects  of
palmitate on secretion of IL-6, IL-8, MCP-1, and HA by
orbital fibroblasts. Orbital fibroblasts were treated with 100–
400 μM palmitate for 24 h. As shown in Figure 4, palmitate
treatment  significantly  induced  IL-6  secretion  in  a  dose
dependent  manner  and  slightly  but  significantly  induced
MCP-1 secretion in orbital fibroblasts. In addition, orbital
fibroblasts secreted higher amounts of IL-6 and MCP-1 under
basal conditions and in response to palmitate, compared with
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1470dermal fibroblasts (Figure 5). However, palmitate did not
increase IL-8 or HA secretion in orbital fibroblasts (Figure 4).
Palmitate  has  been  implicated  in  various  biologic
phenomena via the ceramide pathway. Ceramide is produced
from palmitate via a de novo synthetic pathway of serine-
palmitoyl transferase [18]. Thus, we examined whether the
palmitate-induced secretion of IL-6 and MCP-1 is dependent
on  de  novo  ceramide  synthesis.  Orbital  fibroblasts  were
pretreated with 10 μM fumonisin B1, an inhibitor of de novo
ceramide  synthesis,  for  1  h  followed  by  treatment  with
palmitate (200 μM) for 24 h. Pre-treatment with fumonisin B1
enhanced rather than inhibited palmitate-induced IL-6 and
MCP-1 secretion from orbital fibroblasts (Figure 6). These
results show that palmitate induces IL-6 and MCP-1 secretion
via a ceramide-independent pathway in orbital fibroblasts.
Regulation of palmitate-induced IL-6 and MCP-1 expression
by MAPKs in orbital fibroblasts: Mitogen-activated protein
kinases (MAPKs) play a key role in regulating fibroblast
cytokine  production.  Previous  studies  have  shown  that
IL-1β-induced IL-6 secretion is mediated by p38 and ERK
pathways in orbital fibroblasts [19] and that IL-18-induced
MCP-1 expression is mediated by JNK in synovial fibroblasts
[20]. Thus, we investigated whether palmitate-induced IL-6
and MCP-1 expression in orbital fibroblasts were mediated by
p38, ERK, and JNK pathways. We initially measured the
levels of phosphorylated p38, ERK, and JNK in palmitate-
treated orbital fibroblasts by immunoblot analysis. As shown
in Figure 7, treatment with palmitate induced p38, ERK, and
JNK phosphorylation in orbital fibroblasts in a time (Figure
7A) and dose (Figure 7B)-dependent manner. Interestingly,
ERK phosphorylation by palmitate occurred in dual peaks, at
0.5 and 24 h.
We  then  examined  the  role  of  MAPKs  in  palmitate-
induced IL-6 and MCP-1 secretion in orbital fibroblasts using
specific inhibitors, such as SB 203580 for p38, PD98059 for
ERK, and SP600125 for JNK. Orbital fibroblasts were treated
for 1 h with or without the designated MAPK inhibitor at
20 μM, followed by treatment with palmitate (400 μM) for 24
h.  Palmitate-induced  IL-6  expression  was  suppressed  by
inhibitors of p38 (SB 203580), ERK (PD98059), and JNK (SP
600125) at both the protein and mRNA levels (Figure 8A,B).
MCP-1 protein and mRNA expression were also suppressed
Figure 1. Characterization of orbital fibroblasts. Orbital fibroblasts were derived from retrobulbar fat tissue of patients with thyroid-associated
ophthalmopathy (n=5, Table 1). Morphology was examined by phase-contrast microscopy and the expression patterns of fibroblast and non-
fibroblast markers were examined by immunostaining with antibodies against vimentin (VIM), α-smooth muscle actin (α-SMA), protein
disulfide-isomerase (PDI), factor VIII, and cytokeratin, respectively. Images were obtained from orbital fibroblasts of a representative patient
with TAO. Similar results were observed in orbital fibroblasts from all five patients with TAO.
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1471by inhibitors of ERK (PD98059) and JNK (SP 600125), but
not by the p38 inhibitor (SB 203580) in palmitate-treated
orbital fibroblasts (Figure 8C,D). These results show that IL-6
and  MCP-1  expression  by  palmitate  were  differentially
regulated by MAPKs. IL-6 expression was mediated by the
p38, ERK, JNK pathways, whereas MCP-1 expression was
mediated by ERK and JNK, but not by p38, in palmitate-
treated orbital fibroblasts.
DISCUSSION
Orbital fibroblasts are sub-grouped into Thy-1-positive and
negative cells. These subsets exhibit distinct phenotypes and
contribute differently to the development of TAO. Thy-1-
positive  cells  are  capable  of  myofibroblast  differentiation
after treatment with transforming growth factor-β and produce
more prostaglandin E2 and HA than that of Thy-1- negative
cells after stimulation with IL-1β or GT1b, whereas Thy-1-
negative  cells  differentiate  into  lipofibroblasts  after
adipogenic stimulation and produce higher levels of IL-8 than
that of Thy-1-positive cells after treatment with IFN-γ [4,21,
22].  Thus,  the  clinical  manifestation  of  TAO  may  vary
depending on the relative proportion of Thy-1-positive and
negative cells. Khoo et al. [23] reported that the proportion of
orbital  Thy-1-positive  cells  increased  from  66.8%  (range,
63.3%–71.0%) in normal fibroblast cultures to 77.9% (range,
66.5%–84.8%) in cultured orbital fibroblasts from patients
with  Grave’s  ophthalmopathy.  In  the  current  study,  the
proportion of Thy-1-positive cells (90.1±7.0%; range, 85.7%–
98.2%),  which  was  derived  from  orbital  fat  explants  of
patients with TAO, in our system was slightly higher, as
compared to the level of a previous report (Figure 2) [23].
Here we demonstrated that orbital fibroblasts secreted
higher amounts of IL-6 and MCP-1 under basal conditions and
in response to palmitate, compared with dermal fibroblasts
(Figure 5). It has been reported that palmitate induces the
secretion of IL-6 and MCP-1 from various types of cells
[12-15]. In addition, Chen et al. [19] reported that orbital
fibroblasts, when treated with IL-1β, expressed higher level
of IL-6 than dermal firborblasts, suggesting that the capacity
of orbital fibroblasts to express pro-inflammatory cytokines
may underlie the particular susceptibility of orbital connective
tissues to immune activation.
Although Ceramide, a metabolite of palmitate, is a well
known inducer of pro-inflammatory cytokines [16], palmitate
induces the production of pro-inflammatory cytokines via a
ceramide-dependent or independent pathway, depending on
the  type  of  palmitate-induced  cytokine  and  the  cell.
Furthermore,  inhibiting  ceramide  synthesis  enhances
palmitate-induced secretion of cytokines in certain cells [12].
Pretreatment  with  triacsin  C,  an  inhibitor  of  acyl-CoA
synthetase in de novo ceramide synthesis, reduces palmitate-
induced secretion of tumor necrosis factor (TNF)-α, IL-8, and
IL-1β  in  human  macrophages  [16],  whereas  pretreatment
augments  palmitate-induced  IL-6  secretion  in  adipocytes
[12]. Our results also show that pretreatment with fuminosin
B1 (Figure 5) or triacsin C (data not shown), inhibitors of de
novo ceramide synthesis, increased rather than inhibited IL-6
and  MCP-1  secretion  from  palmitate-treated  orbital
fibroblasts. The biochemical mechanism of how inhibiting
ceramide synthesis enhances secretion of IL-6 and MCP-1 is
unclear, but sphinganine, sphingosine, and their 1-phosphate
metabolites,  which  increase  when  ceramide  synthesis  is
inhibited by fumonisin B1, are likely to participate in this
regulation. In particular, sphigosine-1-phosphate appears to
have both pro- and anti-inflammatory effects depending on
the cell context [24]. In addition, we considered the direct
Figure  2.  Flow  cytometry  analysis  of
Thy-1 expression in orbital fibroblasts.
Orbital  fat-derived  fibroblasts  were
stained  with  a  PE-Cy5-IgG  κ  isotype
and  a  PE-Cy5-anti-Thy-1  antibody,
respectively,  and  then  analyzed  by  a
flow cytometry. Data are obtained from
orbital  fibroblasts  of  a  representative
patient with TAO.
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1472effect  of  fumonisin  B1  on  IL-6  and  MCP-1  secretion,  as
treatment of mice with fumonisin B1 increases levels of IL-12,
TNF-α, interferon γ, and IL-1 in mouse tissues [25]. However,
in our pilot study, treatment with 10 μM fumonisin B1 had no
effect on IL-6 or MCP-1 secretion in RAW 264.7 cells (data
not shown).
In the context of TAO immunological features, IL-6 and
PCP-1 play an important role in lymphocyte function. IL-6
not only drives the synthesis of immunoglobulins in B cells
but also induces Th2 differentiation in T cells [26]. Hiromatsu
et al. [26] reported that IL-6 mRNA is highly expressed in
extra-ocular eye muscles and orbital fat tissue in patients with
TAO, and that its level is positively correlated with orbital
volume, showing the importance of IL-6 in the pathogenesis
of  TAO.  Additionally,  MCP-1  also  contributes  to  the
development of TAO by attracting leukocytes. MCP-1 mRNA
is highly expressed in orbital adipose tissues of patients with
TAO,  compared  with  that  in  orbital  adipose  tissues  from
healthy donors [27].
Interestingly,  the  action  of  p38  on  IL-6  and  MCP-1
production  was  different  in  palmitate-treated  orbital
fibroblasts, although palmitate induced phosphorylation of all
MAPKs such as p38, ERK, and JNK (Figure 6). Pre-treatment
with inhibitors of p38 (SB 203580), ERK (PD98059), and
JNK (SP 600125) suppressed IL-6 expression in palmitate-
treated orbital fibroblasts, whereas MCP-1 was suppressed by
inhibitors of ERK (PD98059) and JNK (SP 600125), but not
by a p38 inhibitor (SB 203580) (Figure 7C,D). While the exact
mechanism  of  IL-6  and  MCP-1  regulation  by  MAPKs  is
unknown,  there  are  several  reports  showing  different  p38
Figure  3.  Secretion  of  IL-6,  IL-8,
MCP-1, and hyaluronic acid (HA) from
orbital fibroblasts in response to IL-1β.
Orbital  fat-derived  fibroblasts  were
treated with IL-1β (10 ng/ml) for 24 h.
Concentrations of IL-6 (A), IL-8 (B),
MCP-1  (C),  and  HA  (D)  were
determined  by  ELISA.  Data  are
presented  as  the  mean±SD  of  three
replicate  culture  wells  from  a
representative  experiment.  Similar
results  were  observed  in  orbital
fibroblasts from #1 and #2 patients with
TAO (Table 1). * p<0.05.
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1473actions between IL-6 and MCP-1. Kito et al. [28] reported that
cyclic strain-induced IL-6 production is regulated by p38,
ERK, and JNK in endothelial cells, whereas Amin et al. [20]
reported that IL-18-induced MCP-1 production in synovial
fibroblasts of patients with rheumatoid arthritis is mediated
by JNK, but not p38.
Plasma FFAs are used as an oxidative energy source and
as a signaling molecule in various tissues such as skeletal
muscle,  liver,  heart,  and  pancreas.  However,  excessive
amounts of FFAs adversely affect health. Plasma FFA levels
increase from 200 to 400 μΜ at a basal level up to 800–1500
μΜ in patients with obesity, type 2 diabetes mellitus [29] and
hyperthyroidism  [6].  Concentrations  of  100–400  μΜ,  at
which  palmitate  significantly  induces  IL-6  and  MCP-1
secretion  in  orbital  fibroblasts,  would  be  pathologically
relevant in patients with hyperthyroidism, as the proportion
Figure 4. Secretion of IL-6 and MCP-1,
but not IL-8 and hyaluronic acid (HA),
from orbital fibroblasts in response to
palmitate.  Orbital  fibroblasts  were
treated  with  palmitate  for  24  h.
Concentrations of IL-6 (A), IL-8 (B),
MCP-1  (C),  and  HA  (D)  were
determined  by  ELISA.  Data  are
presented  as  the  mean±SD  of  three
replicate  culture  wells  from  a
representative  experiment.  Similar
results  were  observed  in  three
independent experiments using orbital
fibroblasts from #1 patient with TAO
(Table 1). * p<0.05 versus non-treated
control cells.
Figure  5.  Higher  levels  of  IL-6  and
MCP-1 secreted from orbital fibroblasts
than from dermal fibroblasts under basal
conditions and in response to palmitate.
Orbital  and  dermal  fibroblasts  were
treated  with  palmitate  for  24  h.
Concentrations of IL-6 (A) and MCP-1
(B) were determined by ELISA. Data
are presented as the mean±SD of three
replicate  culture  wells  from  a
representative  experiment.  Similar
results  were  observed  in  three
independent experiments using orbital
fibroblasts from #1 patient with TAO
(Table 1). * p<0.05 versus cells treated
with same concentration of palmitate.
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1474of palmitate in FFAs is about 25% [30] and plasma FFAs
levels  increase  to  800–1,000  μΜ  in  patients  with
hyperthyroidism [6].
FFA  exists  as  albumin-bound  and  unbound  forms.
Although 99% or more of FFAs are bound to albumin, the
small fraction of unbound FFA is the physiologically more
active  form  [31].  In  the  current  study,  we  directly  added
palmitate-dissolved in NaOH/Et-OH to the culture media to
reduce the effect of endotoxin. We dissolved palmitate in
NaOH/Et-OH rather than conjugating palmitate with BSA.
Schwartz  et  al.  [17]  raised  the  problem  of  endotoxin
contamination even after using a low-endotoxin preparation
of BSA while preparing FFA/BSA complexes. In that report,
the authors recommended a new method for preparing FFA
that we used in this study. In our pilot study, we also detected
endotoxin contamination in palmitate-bound to BSA using the
ToxinSensorTM  Endotoxin  Detection  System  (GenScript,
Piscataway, NJ; data not shown). Consistent with this result,
treatment  with  palmitate-bound  to  BSA  significantly
increased TNF-α production up to 40 fold higher than that of
palmitate-dissolved  in  NaOH/Et-OH  (data  not  shown).
Furthermore, we found that palmitate-dissolved in NaOH/Et-
OH was less toxic to RAW 264.7 cells than palmitate-bound
to BSA in our pilot study (data not shown). Although, it is
uncertain what proportion of palmitate is bound to serum
albumin or left in an unbound state when palmitate is directly
added  to  culture  media,  we  used  palmitate-dissolved  in
NaOH/Et-OH  instead  of  palmitate-bound  to  BSA,  as
endotoxin could affect palmitate.
There may be limitations to generalizing our results in
that TAO not only occurs in hyperthyroid patients but also
occurs in hypothyroid and euthyroid patients. Clinical studies
Figure 6. Effect of fumonisin B1 on the
palmitate-induced  IL-6  and  MCP-1
secretion  from  orbital  fibroblasts.
Orbital fibroblasts were pretreated with
fuminosin B1 (10 μM) for 1 h, followed
by treatment with palmitate (200 μM)
for 24 h. Concentrations of IL-6 (A) and
MCP-1 (B) were determined by ELISA.
Data are presented as the mean±SD of
three  replicate  culture  wells  from  a
representative  experiment.  Similar
results  were  observed  in  three
independent experiments using orbital
fibroblasts from #1 patient with TAO
(Table 1). * p<0.05.
Figure 7. Effect of palmitate on p38,
ERK,  and  JNK  phosphorylation  in
orbital  fibroblasts.  Orbital  fibroblasts
were treated with palmitate (200 μM)
for  0.5–  24  h  (A)  or  treated  with
palmitate  (50–200  μM)  for  24  h  (B).
Levels  of  phosphorylated  p38,  ERK,
and  JNK  were  determined  by
immunoblot  analysis.  Data  are
representative  of  three  independent
experiments  using  orbital  fibroblasts
from #1, #3, and #4 patients with TAO
(Table 1).
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1475are needed to define whether or how palmitate contributes to
the development of TAO. However, our results demonstrate
the  possible  involvement  of  palmitate  in  promoting
inflammation within orbital tissues and, subsequently, in the
development of TAO.
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